- Home
- CCCC vs SHOE Comparison
CCCC vs SHOE Comparison
Compare CCCC & SHOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCCC | SHOE |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 457.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCCC | SHOE |
|---|---|---|
| Price | $4.25 | $15.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 582.0K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.40 | $15.19 |
| 52 Week High | $4.60 | $16.29 |
Technical Indicators
Market Signals| Indicator | CCCC | SHOE |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | N/A |
| Support Level | $2.10 | N/A |
| Resistance Level | $4.60 | N/A |
| Average True Range (ATR) | 0.36 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 72.60 | 0.00 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.